524684-52-4
基本信息
2-(3-氟-4-羥基苯基)-7-乙烯基-1,3-苯并惡唑-5-醇
PRINABEREL
WAY-202041
Prinaberel (ERB 041)
2-(3-Fluoro-4-hydroxyphenyl)- 7-vinylbenzoxazol-5-ol
7-Ethenyl-2-(3-fluoro-4-hydroxyphenyl)-5-benzoxazolol
5-Benzoxazolol, 7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-
2-(3-Fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
物理化學(xué)性質(zhì)
常見問題列表
hERβ 5.4 nM (IC 50 ) |
rat ERβ 3.1 nM (IC 50 ) |
mouse ERβ 3.7 nM (IC 50 ) |
hERα 1200 nM (IC 50 ) |
mouse ERα 750 nM (IC 50 ) |
rat ERα 620 nM (IC 50 ) |
Prinaberel (ERB-041) (0-60 μM; 24 hours) treatment of human SCC cells induces cell differentiation, cell cycle arrest and reduces colony formation.
Prinaberel shows a marked reduction in the expression of inflammation regulatory proteins such as p-NFκBp65, iNOS and COX-2 in A431 cells. Prinaberel diminishes phosphorylated-PI3K and -AKT, which is associated with the enhancement in E-cadherin expression and reduction in migration of A431 cells.
Prinaberel (0.01-10 μM) inhibits cell proliferation in a dose- and time-dependent manner.
Prinaberel (10 μM; 48 hours) promotes ovarian cancer (SKOV-3 cells) apoptosis.
Western Blot Analysis
Cell Line: | A431 cells |
Concentration: | 0, 20, 40 and 60 μM |
Incubation Time: | 24 hours |
Result: | Reduction in the expression of G1 cyclins (D1, D2 and D3) and CDK4. |
Cell Proliferation Assay
Cell Line: | SKOV-3, A2780CP or OVCAR-3 cells |
Concentration: | 0.01, 0.1 and 10 μM |
Incubation Time: | 24-48 hours |
Result: | Showed significantly inhibitory effect on cell proliferation. |
Prinaberel (2mg/mouse; topically; 30 min prior to UVB irradiation for 30 weeks) suppresses development of squamous cell carcinoma in SKH-1 hairless mice.
Prinaberel reduces proliferation and angiogenesis and induces apoptosis in UVB-induced skin tumors. Prinaberel suppresses pro-inflammatory signaling pathway in UVB-induced skin tumors. Prinaberel diminished tumor invasiveness via PI3K-AKT pathway and WNT signaling.
Animal Model: | Six- to eight-weeks-old SKH-1 hairless female mice |
Dosage: | 2 mg/mouse in 200μl ethanol |
Administration: | Topically; 30 min prior to UVB (180mJ/cm2) irradiation for 30 weeks |
Result: | Diminished UVB-induced skin tumor development in SKH-1 hairless mice. |